| __timestamp | Halozyme Therapeutics, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 381287000 |
| Thursday, January 1, 2015 | 40028000 | 452612000 |
| Friday, January 1, 2016 | 45853000 | 316800000 |
| Sunday, January 1, 2017 | 53816000 | 330100000 |
| Monday, January 1, 2018 | 60804000 | 265800000 |
| Tuesday, January 1, 2019 | 77252000 | 336200000 |
| Wednesday, January 1, 2020 | 45736000 | 423900000 |
| Friday, January 1, 2021 | 50323000 | 467000000 |
| Saturday, January 1, 2022 | 143526000 | 487000000 |
| Sunday, January 1, 2023 | 149182000 | 477100000 |
| Monday, January 1, 2024 | 154335000 |
Data in motion
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, United Therapeutics Corporation and Halozyme Therapeutics, Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, United Therapeutics consistently maintained higher SG&A costs, peaking at nearly 480% more than Halozyme in 2022. This reflects their expansive operational strategies and market reach. Meanwhile, Halozyme's SG&A expenses surged by over 300% from 2014 to 2023, indicating a strategic shift towards growth and expansion. Notably, 2022 marked a significant year for both companies, with Halozyme's expenses nearly quadrupling from 2014 levels, suggesting aggressive scaling efforts. This analysis underscores the dynamic nature of biotech operations and the strategic decisions that drive financial outcomes.
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: AbbVie Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue: Key Insights for United Therapeutics Corporation and Halozyme Therapeutics, Inc.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Verona Pharma plc
United Therapeutics Corporation vs Ultragenyx Pharmaceutical Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Alkermes plc
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Geron Corporation
Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs Halozyme Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Taro Pharmaceutical Industries Ltd.